--News Direct--

By Johnny Rice, Benzinga

Al Altomari, Chairman and CEO of Agile Therapeutics Inc (NASDAQ: AGRX), was recently interviewed by Benzinga.

Agile Therapeutics says it is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Its products and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method.

The company’s flagship product is Twirla® (levonorgestrel and ethinyl estradiol), a non-daily prescription contraceptive utilizing a transdermal system. Twirla is based on proprietary transdermal patch technology, called Skinfusion®, designed to allow drug delivery through the skin.

Watch the full interview here:

Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Matt Riley - Head of Investor Relations & Corporate Communications

mriley@agiletherapeutics.com

https://agiletherapeutics.com/

View source version on newsdirect.com: https://newsdirect.com/news/agile-therapeutics-this-biopharma-firm-is-nimbly-solving-unmet-needs-for-women-978586482